We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0REN market cap is 72.78B. The company's latest EPS is USD 2.3123 and P/E is 38.57.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.35B | 4.39B | 5.23B | 5.38B | 6B |
| Operating Income | 1.15B | 897.6M | 1.57B | 1.71B | 1.51B |
| Net Income | 1.05B | 823.4M | 1.5B | 1.52B | 1.4B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 6.49B | 7.24B | 8.5B | 8.29B | 9.36B |
| Total Liabilities | 2.34B | 2.66B | 2.67B | 2.49B | 2.64B |
| Total Equity | 4.15B | 4.57B | 5.84B | 5.81B | 6.72B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 1.18B | 1.05B | 1.73B | 1.22B | 895.8M |
| Investing | -595.8M | -531.1M | -1.72B | 252.3M | 173.8M |
| Financing | -115.6M | -486.9M | -356.3M | -1.58B | -711M |
| Market Cap | 72.78B |
| Price to Earnings Ratio | 38.57 |
| Price to Sales Ratio | 9.01 |
| Price to Cash Ratio | 47.29 |
| Price to Book Ratio | 8.05 |
| Dividend Yield | - |
| Shares Outstanding | 606.5M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 46 |
| 52 Week Change | 0.00% |
| 52 Week High | 120.00 |
| 52 Week Low | 120.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Edwards Lifesciences Corp |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.edwards.com |
| Industry | ortho,prosth,surg appl,suply (3842) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
